View Financial HealthS.C. Ropharma 배당 및 자사주 매입배당 기준 점검 0/6S.C. Ropharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026공시 • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, RomaniaNew Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).공시 • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, RomaniaNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).분석 기사 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).분석 기사 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.분석 기사 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.분석 기사 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.분석 기사 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.분석 기사 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...분석 기사 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RPH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RPH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장S.C. Ropharma 배당 수익률 vs 시장RPH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RPH)n/a시장 하위 25% (RO)1.7%시장 상위 25% (RO)6.4%업계 평균 (Consumer Retailing)3.5%분석가 예측 (RPH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RPH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RPH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RPH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RPH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YRO 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 10:21종가2026/05/21 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스S.C. Ropharma S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 28S.C. Ropharma S.A. to Report Fiscal Year 2025 Results on Apr 28, 2026S.C. Ropharma S.A. announced that they will report fiscal year 2025 results on Apr 28, 2026
공시 • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026S.C. Ropharma S.A., Annual General Meeting, Apr 27, 2026, at 12:00 E. Europe Standard Time. Location: company s headquarters in brasov, 55, iuliu maniu street, Romania
New Risk • Jan 01New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON92.0m market cap, or US$21.2m).
Reported Earnings • Dec 27Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON392.9m (up 12% from 3Q 2024). Net income: RON3.93m (up 429% from 3Q 2024). Profit margin: 1.0% (up from 0.2% in 3Q 2024). The increase in margin was driven by higher revenue.
New Risk • Sep 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 38% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (RON91.0m market cap, or US$21.3m).
New Risk • May 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RON78.2m market cap, or US$17.2m).
Reported Earnings • May 09Full year 2024 earnings releasedFull year 2024 results: Revenue: RON1.33b (up 19% from FY 2023). Net loss: RON1.73m (down 122% from profit in FY 2023).
공시 • Mar 27S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025S.C. Ropharma S.A., Annual General Meeting, Apr 28, 2025, at 12:30 E. Europe Standard Time. Location: at st. constantine hospital conference room in, brasov, 318 calea bucuresti, Romania
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON79.2m market cap, or US$17.4m).
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON81.8m market cap, or US$17.1m).
분석 기사 • Dec 06S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
New Risk • Sep 06New major risk - Revenue and earnings growthEarnings have declined by 2.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.003% net profit margin). Market cap is less than US$100m (RON91.5m market cap, or US$20.4m).
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (RON97.7m market cap, or US$21.4m).
분석 기사 • Dec 09Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
분석 기사 • Sep 23S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of ReturnFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
분석 기사 • Jun 01Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (7 non-independent directors). Member of the Board of Directors Ovidiu Nut was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
분석 기사 • Mar 16Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Price Target Changed • Jul 26Price target decreased to RON0.23Down from RON0.38, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of RON0.22. Stock is down 7.5% over the past year.
분석 기사 • May 15S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Mar 26S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital EffectivelyFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Is New 90 Day High Low • Feb 09New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 11 November 2020. The Romanian market is up 17% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 6.0% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: RON0.24The company is up 8.0% from its price of RON0.22 on 15 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Consumer Retailing industry, which is also up 8.0% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: RON0.24The company is up 6.0% from its price of RON0.22 on 01 October 2020. The Romanian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 4.0% over the same period.
분석 기사 • Dec 23Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
분석 기사 • Nov 24We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A GuideStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said...
Is New 90 Day High Low • Nov 16New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 18 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: RON0.21The company is down 11% from its price of RON0.24 on 30 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 2.0% over the same period.
Reported Earnings • Oct 09First half earnings releasedOver the last 12 months the company has reported total profits of RON5.44m, down 40% from the prior year. Total revenue was RON768.4m over the last 12 months, largely unchanged from the prior year.
Is New 90 Day High Low • Oct 08New 90-day low: RON0.22The company is down 24% from its price of RON0.29 on 09 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: RON0.22The company is down 23% from its price of RON0.29 on 26 June 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period.